Amrutanjan Health Care Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-20
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|
| Sales | 94 Cr | 118 Cr | 141 Cr |
| Operating expenses (approx.) | 81 Cr | 97 Cr | 113 Cr |
| EBITDA | 13 Cr | 21 Cr | 28 Cr |
| OPM % | 13.7% | 17.7% | 19.9% |
| Other income | 4 Cr | 4 Cr | 4 Cr |
| Interest | 0.05 Cr | 0.05 Cr | 0.05 Cr |
| Depreciation | 2 Cr | 2 Cr | 2 Cr |
| Profit before tax | 11 Cr | 19 Cr | 26 Cr |
| Tax % | 26.4% | 27.3% | 26.2% |
| Net profit | 8 Cr | 14 Cr | 19 Cr |
| EPS (₹) | ₹2.87 | ₹4.83 | ₹6.73 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 452 Cr | Sign in for TTM |
| Operating expenses (approx.) | 376 Cr | Sign in for TTM |
| EBITDA | 76 Cr | Sign in for TTM |
| OPM % | 16.8% | Sign in for TTM |
| Other income | 18 Cr | Sign in for TTM |
| Interest | 0.22 Cr | Sign in for TTM |
| Depreciation | 7 Cr | Sign in for TTM |
| Profit before tax | 69 Cr | Sign in for TTM |
| Tax % | 26.5% | Sign in for TTM |
| Net profit | 51 Cr | Sign in for TTM |
| EPS (₹) | ₹17.58 | Sign in for TTM |
| Dividend payout % | 26.1% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 3 Cr |
| Reserves | 324 Cr |
| Borrowings | — |
| Other liabilities | 95 Cr |
| Total liabilities | 421 Cr |
| Fixed assets (net) | 48 Cr |
| CWIP | 16 Cr |
| Investments | 0.0000 Cr |
| Other assets | 291 Cr |
| Total assets | 421 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 51 Cr |
| Cash from investing | -31 Cr |
| Cash from financing | -13 Cr |
| Net cash flow | 6 Cr |
| Free cash flow (OCF − Capex) | 15 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 21.2% |
| ROE % | 15.6% |
| Debtor days | — |
| Inventory days | 99 |
| Days payable | — |
| Cash conversion cycle | 99 |
| Debt / equity | — |
| Current ratio | 3.44 |
| Net debt / EBITDA | -0.13 |
Compare with peers
Loading peers…